Endocrine disruptors (EDs) are compounds that interfere with the balance of the endocrine system by mimicking or antagonising the effects of endogenous hormones, by altering the synthesis and metabolism of natural hormones, or by modifying hormone receptor levels. The synthetic estrogen 17α-ethinylestradiol (EE2) and the environmental carcinogen benzo[a]pyrene (BaP) are exogenous EDs whereas the estrogenic hormone 17β-estradiol is a natural endogenous ED. Although the biological effects of these individual EDs have partially been studied previously, their toxicity when acting in combination has not yet been investigated. Here we treated Wistar rats with BaP, EE2 and estradiol alone or in combination and studied the influence of EE2 and estradiol on: (i) the expression of cytochrome P450 (CYP) 1A1 and 1B1 in rat liver on the transcriptional and translational levels; (ii) the inducibility of these CYP enzymes by BaP in this rat organ; (iii) the formation of BaP-DNA adducts in rat liver in vivo; and (iv) the generation of BaP-induced DNA adducts after activation of BaP with hepatic microsomes of rats exposed to BaP, EE2 and estradiol and with recombinant rat CYP1A1 in vitro. BaP acted as a strong and moderate inducer of CYP1A1 and 1B1 in rat liver, respectively, whereas EE2 or estradiol alone had no effect on the expression of these enzymes. However, when EE2 was administered to rats together with BaP, it significantly decreased the potency of BaP to induce CYP1A1 and 1B1 gene expression. For EE2, but not estradiol, this also correlated with a reduction of BaP-induced CYP1A1 enzyme activity in rat hepatic microsomes. Further, while EE2 and estradiol did not form covalent adducts with DNA, they affected BaP-derived DNA adduct formations in vivo and in vitro. The observed decrease in BaP-DNA adduct levels in rat liver in vivo resulted from the inhibition of CYP1A1-mediated BaP bioactivation by EE2 and estradiol. Our results indicate that BaP genotoxicity mediated through its activation by CYP1A1 in rats in vivo is modulated by estradiol and its synthetic derivative EE2.

Department of Analytical Environmental and Forensic Sciences MRC PHE Centre for Environment and Health King's College London 150 Stamford Street London SE1 9NH United Kingdom

Department of Biochemistry Faculty of Science Charles University Albertov 2030 128 40 Prague 2 Czech Republic

Division of Radiopharmaceutical Chemistry German Cancer Research Center Im Neuenheimer Feld 280 69120 Heidelberg Germany

Zobrazit více v PubMed

Alexandrov L.B., Ju Y.S., Haase K., Van Loo P., Martincorena I., Nik-Zainal S., Totoki Y., Fujimoto A., Nakagawa H., Shibata T., Campbell P.J., Vineis P., Phillips D.H., Stratton M.R. Mutational signatures associated with tobacco smoking in human cancer. Science. 2016;354:618–622. PubMed PMC

Arlt V.M., Stiborova M., Henderson C.J., Thiemann M., Frei E., Aimova D., Singh R., Gamboa da Costa G., Schmitz O.J., Farmer P.B., Wolf C.R., Phillips D.H. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis. 2008;29:656–665. PubMed

Arlt V.M., Poirier M.C., Sykes S.E., John K., Moserova M., Stiborova M., Wolf C.R., Henderson C.J., Phillips D.H. Exposure to benzo[a]pyrene of hepatic cytochrome P450 reductase null (HRN) and P450 reductase conditional null (RCN) mice: detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling. Toxicol. Lett. 2012;213:160–166. PubMed PMC

Arlt V.M., Krais A.M., Godschalk R.W., Riffo-Vasquez Y., Mrizova I., Roufosse C.A., Corbin C., Shi Q., Frei E., Stiborova M., van Schooten F.J., Phillips D.H., Spina D. Pulmonary inflammation impacts on CYP1A1-mediated respiratory tract DNA damage induced by the carcinogenic air pollutant benzo[a]pyrene. Toxicol. Sci. 2015;146:213–225. PubMed PMC

Back D.J., Maggs J.L., Purba H.S., Newby S., Park B.K. 2-Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine. Br. J. Clin. Pharmacol. 1984;18:603–607. PubMed PMC

Badawi A.F., Cavalieri E.L., Rogan E.G. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism. 2001;50:1001–1003. PubMed

Baird W.M., Hooven L.A., Mahadevan B. Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. Environ. Mol. Mutagen. 2005;45:106–114. PubMed

Bolt H.M. Metabolism of estrogens-natural and synthetic. Pharmacol. Ther. 1979;4:155–181. PubMed

Borek-Dohalska L., Valaskova P., Cerna V., Stiborova M. Role of rat cytochromes P450 in the oxidation of 17α-ethinylestradiol. Environ. Toxicol. Pharmacol. 2014;38:852–860. PubMed

Borek-Dohalska L., Valaskova P., Kubickova B., Sulc M., Kresinova Z., Cajthaml T., Stiborova M. A study on 17alpha-ethinylestradiol metabolism in rat and Pleurotus ostreatus. Neuro Endocrinol. Lett. 2015;36:5–12. PubMed

Cavalieri E.L., Rogan E.G. Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention. Clin. Transl. Med. 2016;5:12. PubMed PMC

Chang S.Y., Chen C., Yang Z., Rodrigues A.D. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. Drug Metab. Dispos. 2009;37:1667–1675. PubMed

Chepelev N.L., Long A.S., Bowers W.J., Gagne R., Williams A., Kuo B., Phillips D.H., Arlt V.M., White P.A., Yauk C.L. Transcriptional profiling of the mouse hippocampus supports an NMDAR-mediated neurotoxic mode of action for benzo[a]pyrene. Environ. Mol. Mutagen. 2016;57:350–363. PubMed PMC

Dawling S., Roodi N., Mernaugh R.L., Wang X., Parl F.F. Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res. 2001;61:6716–6722. PubMed

Fang A.H., Smith W.A., Vouros P., Gupta R.C. Identification and characterization of a novel benzo[a]pyrene-derived DNA adduct. Biochem. Biophys. Res. Commun. 2001;281:383–389. PubMed

Henderson M.C., Miranda C.L., Stevens J.F., Deinzer M.L., Buhler D.R. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica. 2000;30:235–251. PubMed

Hockley S.L., Arlt V.M., Brewer D., Te Poele R., Workman P., Giddings I., Phillips D.H. AHR- and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines. Chem. Res. Toxicol. 2007;20:1797–1810. PubMed

Hockley S.L., Arlt V.M., Jahnke G., Hartwig A., Giddings I., Phillips D.H. Identification through microarray gene expression analysis of cellular responses to benzo(a)pyrene and its diol-epoxide that are dependent or independent of p53. Carcinogenesis. 2008;29:202–210. PubMed

Hodek P., Koblihová J., Kizek R., Frei E., Arlt V.M., Stiborová M. The relationship between DNA adduct formation by benzo[a]pyrene and expression of its activation enzyme cytochrome P450 1A1 in rat. Environ. Toxicol. Pharmacol. 2013;36:989–996. PubMed

IARC Sex hormones (II) IARC Monogr. Eval. Carcinog. Risks Hum. 1979:21.

IARC Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. IARC Monogr. Eval. Carcinog. Risks Hum. 2010:92. PubMed PMC

Indra R., Moserova M., Sulc M., Frei E., Stiborova M. Oxidation of carcinogenic benzo[a]pyrene by human and rat cytochrome P450 1A1 and its influencing by cytochrome b5–a comparative study. Neuro Endocrinol. Lett. 2013;34:55–63. PubMed

Indra R., Moserova M., Kroftova N., Sulc M., Martinkova M., Adam V., Eckschlager T., Kizek R., Arlt V.M., Stiborova M. Modulation of human cytochrome P450 1A1-mediated oxidation of benzo[a]pyrene by NADPH:cytochrome P450 oxidoreductase and cytochrome b5. Neuro Endocrinol. Lett. 2014;35:105–113. PubMed

Klinger W., Lupp A., Karge E., Baumbach H., Eichhorn F., Feix A., Füldner F., Gernhardt S., Knels L., Kost B., Mertens G., Werner F., Oettel M., Römer W., Schwarz S., Elger W., Schneider B. Estradiol, testosterone, dehydroepiandrosterone and androstenedione: novel derivatives and enantiomers. Interactions with rat liver microsomal cytochrome P450 and antioxidant/radical scavenger activities in vitro. Toxicol. Lett. 2002;128:129–144. PubMed

Krais A.M., Speksnijder E.N., Melis J.P., Indra R., Moserova M., Godschalk R.W., van Schooten F.J., Seidel A., Kopka K., Schmeiser H.H., Stiborova M., Phillips D.H., Luijten M., Arlt V.M. The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice. Arch. Toxicol. 2016;90:839–851. PubMed PMC

Kucab J.E., van Steeg H., Luijten M., Schmeiser H.H., White P.A., Phillips D.H., Arlt V.M. TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts. Mutat. Res. 2015;773:48–62. PubMed PMC

Lee A.J., Cai M.X., Thomas P.E., Conney A.H., Zhu B.T. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003;144:3382–3398. PubMed

Liehr J.G. Is estradiol a genotoxic mutagenic carcinogen? Endocr. Rev. 2000;21:40–54. PubMed

Long A.S., Lemieux C.L., Arlt V.M., White P.A. Tissue-specific in vivo genetic toxicity of nine polycyclic aromatic hydrocarbons assessed using the Muta™Mouse transgenic rodent assay. Toxicol. Appl. Pharmacol. 2016;290:31–42. PubMed PMC

Long A.S., Wills J.W., Krolak D., Guo M., Dertinger S.D., Arlt V.M., White P.A. Benchmark dose analyses of multiple genetic toxicity endpoints permit robust, cross-tissue comparisons of MutaMouse responses to orally delivered benzo[a]pyrene. Arch. Toxicol. 2018;92:967–982. PubMed PMC

Luch A., Baird W.M. Metabolic activation and detoxification of polycyclic aromatic hydrocarbons. In: Luch A., editor. The Carcinogenic Effects of Polycyclic Aromatic Hydrocarbons. Imperial College Press; London: 2005. pp. 19–96.

Nebert D.W., Shi Z., Galvez-Peralta M., Uno S., Dragin N. Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences–Cyp1 knockout mouse lines as a paradigm. Mol. Pharmacol. 2013;84:304–313. PubMed PMC

Nedelcheva V., Gut I. P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica. 1994;24:1151–1175. PubMed

Nesnow S., Ross J., Nelson G., Holden K., Erexson G., Kligerman A., Gupta R.C. Quantitative and temporal relationships between DNA adduct formation in target and surrogate tissues: implications for biomonitoring. Environ. Health Perspect. 1993;101(Suppl. 3):37–42. PubMed PMC

Nik-Zainal S., Kucab J.E., Morganella S., Glodzik D., Alexandrov L.B., Arlt V.M., Weninger A., Hollstein M., Stratton M.R., Phillips D.H. The genome as a record of environmental exposure. Mutagenesis. 2015;30:763–770. PubMed PMC

Nishida C.R., Everett S., Ortiz de Montellano P.R. Specificity determinants of CYP1B1 estradiol hydroxylation. Mol. Pharmacol. 2013;84:451–458. PubMed PMC

Reed L., Mrizova Y., Barta F., Indra R., Moserova M., Kopka K., Schmeiser H.H., Wolf C.R., Henderson C.J., Stiborova M., Phillips D.H., Arlt V.M. Cytochrome b5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in Hepatic Cytochrome b5/P450 Reductase Null (HBRN) mice. Arch. Toxicol. 2018;92:1625–1638. PubMed PMC

Rogers S.M., Back D.J., Orme M.L. Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers. Br. J. Clin. Pharmacol. 1987;23:727–734. PubMed PMC

Schmeiser H.H., Stiborova M., Arlt V.M. 32P-postlabeling analysis of DNA adducts. Methods Mol. Biol. 2013;1044:389–401. PubMed

Schoket B., Levay K., Phillips D.H., Vincze I. 32P-postlabelling analysis of DNA adducts of benzo[a]pyrene formed in complex metabolic activation systems in vitro. Cancer Lett. 1989;48:67–75. PubMed

Shiizaki K., Kawanishi M., Yagi T. Modulation of benzo[a]pyrene-DNA adduct formation by CYP1 inducer and inhibitor. Genes Environ. 2017;39:14. PubMed PMC

Siddens L.K., Larkin A., Krueger S.K., Bradfield C.A., Waters K.M., Tilton S.C., Pereira C.B., Löhr C.V., Arlt V.M., Phillips D.H., Williams D.E., Baird W.M. Polycyclic aromatic hydrocarbons as skin carcinogens: comparison of benzo[a]pyrene, dibenzo[def,p]chrysene and three environmental mixtures in the FVB/N mouse. Toxicol. Appl. Pharmacol. 2012;264:377–386. PubMed PMC

Siddique Y.H., Beg T., Afzal M. Genotoxic potential of ethinylestradiol in cultured mammalian cells. Chem. Biol. Interact. 2005;151:133–141. PubMed

Stanczyk F.Z., Archer D.F., Bhavnani B.R. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87:706–727. PubMed

Stiborová M., Martínek V., Rýdlová H., Hodek P., Frei E. Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res. 2002;62:5678–5684. PubMed

Stiborová M., Martínek V., Rýdlová H., Koblas T., Hodek P. Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett. 2005;220:145–154. PubMed

Stiborová M., Dračínská H., Mizerovská J., Frei E., Schmeiser H.H., Hudeček J., Hodek P., Phillips D.H., Arlt V.M. The environmental pollutant and carcinogen 3-nitrobenzanthrone induces cytochrome P450 1A1 and NAD(P)H:quinone oxidoreductase in rat lung and kidney, thereby enhancing its own genotoxicity. Toxicology. 2008;247:11–22. PubMed

Stiborová M., Dračínská H., Martínek V., Svášková D., Hodek P., Milichovský J., Hejduková Ž., Brotánek J., Schmeiser H.H., Frei E. Induced expression of cytochrome P450 1A and NAD(P)H:quinone oxidoreductase determined at mRNA, protein and enzyme activity levels in rats exposed to the carcinogenic azo dye 1-phenylazo-2-naphthol (Sudan I) Chem. Res. Toxicol. 2013;26:290–299. PubMed

Stiborova M., Moserova M., Cerna V., Indra R., Dracinsky M., Sulc M., Henderson C.J., Wolf C.R., Schmeiser H.H., Phillips D.H., Frei E., Arlt V.M. Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions. Toxicology. 2014;318:1–12. PubMed

Stiborová M., Bárta F., Levová K., Hodek P., Schmeiser H.H., Arlt V.M., Martínek V. A mechanism of O-demethylation of aristolochic acid I by cytochromes P450 and their contributions to this reaction in human and rat livers: experimental and theoretical approaches. Int. J. Mol. Sci. 2015;16:27561–27775. PubMed PMC

Stiborova M., Indra R., Moserova M., Sulc M., Hodek P., Frei E., Schmeiser H.H., Arlt V.M. NADPH- and NADH-dependent metabolism of and DNA adduct formation by benzo[a]pyrene catalyzed with rat hepatic microsomes and cytochrome P450 1A1. Monatsh. Chem. 2016;147:847–855. PubMed PMC

Stiborova M., Indra R., Moserova M., Frei E., Schmeiser H.H., Kopka K., Phillips D.H., Arlt V.M. NADH:Cytochrome b5 reductase and cytochrome b5 can act as sole electron donors to human cytochrome P450 1A1-mediated oxidation and DNA adduct formation by benzo[a]pyrene. Chem. Res. Toxicol. 2016;29:1325–1334. PubMed PMC

Sulc M., Indra R., Moserova M., Schmeiser H.H., Frei E., Arlt V.M., Stiborova M. The impact of individual cytochrome P450 enzymes on oxidative metabolism of benzo[a]pyrene in human livers. Environ. Mol. Mutagen. 2016;57:229–235. PubMed PMC

Uppstad H., Øvrebø S., Haugen A., Mollerup S. Importance of CYP1A1 and CYP1B1 in bioactivation of benzo[a]pyrene in human lung cell lines. Toxicol. Lett. 2010;192:221–228. PubMed

Vale N., Gouveia M.J., Rinaldi G., Santos J., Santos L.L., Brindley P.J., da Costa J.M. The role of estradiol metabolism in urogenital schistosomiasis-induced bladder cancer. Tumour Biol. 2017;39 PubMed

Večeřa R., Zachařová A., Orolin J., Strojil J., Skottová N., Anzenbacher P. Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Biopharm. Drug Dispos. 2011;32:482–487. PubMed

Wang S., Dunlap T.L., Howell C.E., Mbachu O.C., Rue E.A., Phansalkar R., Chen S.N., Pauli G.F., Dietz B.M., Bolton J.L. Hop (Humulus lupulus L.) extract and 6-prenylnaringenin induce P450 1A1 catalyzed estrogen 2-hydroxylation. Chem. Res. Toxicol. 2016;29:1142–1150. PubMed PMC

Wohak L.E., Krais A.M., Kucab J.E., Stertmann J., Ovrebo S., Seidel A., Phillips D.H., Arlt V.M. Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53-dependent mechanism. Arch. Toxicol. 2016;90:291–304. PubMed PMC

Zachařová A., Siller M., Spičáková A., Anzenbacherová E., Skottová N., Anzenbacher P., Večeřa R. Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Xenobiotica. 2012;42:731–736. PubMed

Zhang H., Cui D., Wang B., Han Y.H., Balimane P., Yang Z., Sinz M., Rodrigues A.D. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin. Pharmacokinet. 2007;46:133–157. PubMed

Zhu B.T., Lee A.J. NADPH-dependent metabolism of 17beta-estradiol and estrone to polar and nonpolar metabolites by human tissues and cytochrome P450 isoforms. Steroids. 2005;70:225–244. PubMed

Benzo[a]pyrene-Induced Genotoxicity in Rats Is Affected by Co-Exposure to Sudan I by Altering the Expression of Biotransformation Enzymes